XOMA Royalty Corporation 以 $15M 的价格收购了 Twist Bioscience 未来里程碑和特许权使用费的 50% 权益，将其投资组合扩展到 100 项资产。 XOMA Royalty Corporation acquires 50% interest in Twist Bioscience's future milestones and royalties for $15M, expanding its portfolio to 100 assets.

XOMA Royalty Corporation 以 1500 万美元的价格从与 Twist Bioscience 合作的 60 多个早期项目中购买了未来里程碑和特许权使用费的 50% 经济权益。 XOMA Royalty Corporation has purchased a 50% economic interest in future milestones and royalties from over 60 partnered early-stage programs with Twist Bioscience for $15 million. 这一购置使XOMA的投资组合增加至100多个资产,包括商业治疗和临床前方案。 This acquisition enhances XOMA's portfolio to over 100 assets, including commercial therapeutics and pre-clinical programs. 交易的目的是改善股东按风险调整的回报率,加强XOMA在生物技术特许使用费部门的地位。 The deal is aimed at improving risk-adjusted returns for shareholders and strengthens XOMA's position in the biotech royalty sector.